Why Lower ApoB Longer Reduces Heart Disease Risk? | T. Dayspring & D. Soffer | EP#430
ApoB is established as a driver of atherosclerosis based on multiple types of evidence including clinical trials, observational studies, and genetic data. Lower ApoB levels for longer periods reduce heart disease risk, with clinical evidence showing continued cardiovascular benefit even when LDL-C is reduced from 70 to 15 mg/dL.
Summary
The speakers discuss why lower ApoB for extended periods reduces heart disease risk. They establish that ApoB is a causal driver of atherosclerosis, supported by multiple lines of evidence: clinical trials, observational studies, survey data, randomized controlled trials, and genetic data from Mendelian randomization studies. Major medical societies, including the European Atherosclerosis Society, have recognized both LDL cholesterol and ApoB as causes of atherosclerotic disease based on this comprehensive evidence base. The speakers reference a landmark study led by Brian Ference that analyzed numerous clinical trials, represented as individual data points on a graph showing baseline LDL-C and post-treatment levels. The key finding from this meta-analysis is that all treatment curves show downward trends in cardiovascular events as LDL-C decreases. Notably, even when LDL-C levels were lowered to very low levels (from 70 to 15 mg/dL), there continued to be further reductions in cardiovascular events, suggesting a dose-response relationship without apparent lower threshold. This combination of diverse evidence types provides strong justification for establishing a cause-and-effect relationship between ApoB/LDL-C levels and atherosclerotic disease.
Key Insights
- Multiple independent lines of evidence—clinical trials, observational studies, randomized controlled data, and Mendelian randomization genetic data—all converge to establish ApoB as a causal driver of atherosclerosis
- The European Atherosclerosis Society and other leading medical societies have formally recognized LDL cholesterol and ApoB as causes of atherosclerotic disease based on comprehensive analysis of etiological evidence
- A meta-analysis by Brian Ference examining multiple clinical trials shows that all treatment curves demonstrate reduced cardiovascular events as LDL-C levels decrease from baseline
- Cardiovascular benefit continues even at very low LDL-C levels, with further event reductions observed when LDL-C is lowered from 70 to 15 mg/dL, suggesting no apparent lower threshold for benefit
- The combination of clinical trial data, observational studies, survey data, and randomized controlled evidence provides sufficient justification for establishing a definitive cause-and-effect relationship between ApoB/LDL-C and atherosclerotic disease
Topics
Transcript
[0:00] What evidence is there that gives you reason to say so? The lower the better, and for the longer term. ApoB is a driver of atherosclerosis . We have a wealth of clinical trials providing evidence pointing to etiological factors in atherosclerosis, as well as observational studies, survey data, randomized controlled data, and now genetic data from Mendelian randomization. And if you put all of this together , as the leading medical societies did—the first was the European [0:31] Atherosclerosis Society—they recognized LDL cholesterol and ApoB as the cause of this disease based on these tests. We have great graphics. Brian Ference was the lead author of this study, where each dot represents one of these clinical trials: baseline…
Full transcript available for MurmurCast members
Sign Up to AccessMore from The Proof with Simon Hill
Cannabis & Sperm Quality: What the Research Actually Shows | EP#431
Cannabis use negatively impacts male fertility through multiple mechanisms including reduced sperm production, quality, and motility, with a dose-response relationship where daily use is considered problematic. Partners of cannabis users experience higher miscarriage rates, and IVF outcomes show lower embryo development rates in men who use cannabis, though the speaker advocates for moderation rather than absolute prohibition.
Can You Actually Reverse Liver Scarring? [Expert Explains] | EP#436
Liver fibrosis and scarring, previously thought to be irreversible, can actually be reversed even in advanced stages of steatotic liver disease. The liver has enormous regenerative potential and can recover from significant damage caused by alcohol or obesity, offering hope that early intervention can restore normal liver function.
Do You Really Need Surgery for a Shoulder Tear? | Howard Luks | EP#438
Most joint and tendon pain in adults stems from lack of support, training, and proper loading rather than injury. Imaging often reveals age-related changes like labral tears that are normal findings over age 40-45 and don't necessarily require surgery, despite what social media doctors claim.
How Microplastics, Phthalates & PFAS May Affect Early Development & How to Reduce Exposure | EP#429
The episode discusses how microplastics, phthalates, and PFAS chemicals pose significant risks to child development during the first thousand days of life, with evidence showing specific harms like impacts on male fetal genital development and premature birth. The speaker emphasizes that systemic change through government regulation is necessary, while offering practical individual strategies to reduce exposure, primarily through avoiding heating food in plastic containers and switching to glass, steel, or natural materials.
How Do Microplastics Affect Babies in the First 1000 Days? | Dr Federica Amati
Dr. Federica Amati discusses how microplastics and related chemicals pose significant health risks to babies during the critical first 1,000 days of life, including documented effects on fetal development, fertility, and birth outcomes. She emphasizes that the problem extends beyond plastic itself to include harmful additives like phthalates and PFAS, and calls for reducing plastic production at its source.